UK markets closed

ALK-Abelló A/S (ALK-B.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
2,728.00-108.00 (-3.81%)
At close: 4:59PM CEST
Full screen
Previous close2,836.00
Open2,806.00
Bid2,738.00 x 0
Ask2,740.00 x 0
Day's range2,716.00 - 2,830.00
52-week range1,964.00 - 3,310.00
Volume13,999
Avg. volume7,585
Market cap29.812B
Beta (5Y monthly)0.28
PE ratio (TTM)546.47
EPS (TTM)4.99
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date16 Mar 2017
1y target estN/A
  • Globe Newswire

    Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

    ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) reports the following transactions: 1.Details of the person discharging managerial responsibility / person closely associateda)NameBertil Lindmark2.Reason for the notificationa)Position/statusMember of the Board of Directorsb)Initial notification/amendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameALK-Abelló A/Sb)LEI529900SGCREUZCZ7P0204.Details of the transact

  • Globe Newswire

    Six-month interim report (Q2) 2021

    ALK reports revenue up 13% with sales growth across its portfolio, outlook updated (unaudited) ALK’s revenue growth increased during Q2 on continued strong momentum for tablet sales and a recovery in sales of legacy products. ALK saw overall revenue growth of 13% for the quarter and tablet sales growth of 23% with better than expected earnings, despite a significant, planned increase in R&D spend. Based on year-to-date results, and improved forecasts for H2, ALK has upgraded its 2021 financial o

  • Globe Newswire

    ALK upgrades its full-year financial outlook

    ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the company is upgrading its full-year financial outlook especially with regards to increasing earnings to reflect an improved sales forecast, as well as cost savings and a minor adjustment to the anticipated timing of clinical development activities. As a result: Revenue is now expected to grow 10-12% in local currencies (previously: 9-12), to reflect an improved sales forecast. Tablet sales growth is now expected at 25% or slightl